CA-GILEAD-SCIENCES,-INC.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today the promotion of Alessandro Riva, MD, to Executive Vice President, Oncology Therapeutics, with responsibility for Gilead’s hematology and oncology programs, including cell therapy research and development. Dr. Riva will become a member of Gilead’s senior leadership team.
Dr. Riva joined Gilead in January 2017 as Senior Vice President, Hematology and Oncology Therapeutic Area Head. He has been instrumental in expanding Gilead’s oncology program with the recent acquisition of Kite Pharma, establishing the company as a leader in the field of cellular therapy. He has also guided the strategy and development of Gilead’s broader oncology pipeline during his tenure.
Prior to joining Gilead, Dr. Riva served as Head, Global Oncology Development at Novartis, where he oversaw the development and worldwide regulatory approval of multiple compounds in a variety of tumor types. He received his bachelor’s degree in Medicine and a Certificate Board in Oncology/Hematology from the School of Medicine of Milan. Earlier in his career, he worked as a physician, treating patients with hematological malignancies at the University Hospital of Milan.
“Alessandro’s vision and insight have helped Gilead broaden and deepen our oncology pipeline through the acquisition of Kite Pharma, and his exceptional leadership has guided the company’s broader hematology/oncology strategy,” said John McHutchison, MD, Executive Vice President, Clinical Research. “In his new role, I am confident that Gilead’s hematology and oncology programs will continue to expand, as we seek to advance new therapies with the potential to transform the treatment of patients with cancer.”
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.
Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000
View source version on businesswire.com: http://www.businesswire.com/news/home/20171017005582/en/
Contact:
Gilead Sciences, Inc.
Investors
Sung Lee, 650-524-7792
or
Media
Amy
Flood, 650-522-5643
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DEWA7.5.2024 20:02:33 CEST | Press release
Mohammed bin Rashid Al Maktoum Global Water Award extends application deadline until end of May
SOLAR-PROMOTION-GMBH7.5.2024 17:54:32 CEST | Press release
Fields and the Sun: Agricultural PV, an Opportunity for the Energy and the Farming Industry
CA-VERIMATRIX7.5.2024 17:46:31 CEST | Press release
Verimatrix XTD Enterprise Suite Triumphs at 2024 Cybersecurity Excellence Awards
CA-ENERGY-VAULT7.5.2024 15:59:30 CEST | Press release
Energy Vault Announces Successful Testing and Commissioning of First EVx 100 MWh Gravity Energy Storage System by China Tianying, Extension of Atlas Renewable Licensing Agreement to 15 Years
SMOKE-FREE-SWEDEN7.5.2024 15:54:29 CEST | Press release
Landmark Report Proves That High Nicotine Use Does Not Lead to High Rates of Health Issues
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom